TARA Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Protara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.17 |
| 52 Week High | US$10.48 |
| 52 Week Low | US$1.60 |
| Beta | 1.82 |
| 1 Month Change | 116.32% |
| 3 Month Change | 182.51% |
| 1 Year Change | 182.51% |
| 3 Year Change | -18.84% |
| 5 Year Change | n/a |
| Change since IPO | -82.77% |
Recent News & Updates
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Dec 10Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Nov 22
Recent updates
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Dec 10Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Nov 22Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?
Aug 08Protara: A Bombed Out Biotech With A Very Positive Skew
Feb 22Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Dec 16We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth
Apr 22The Prognosis For Protara Therapeutics
Oct 13Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation
Sep 12Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
Mar 21Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?
Dec 06Shareholder Returns
| TARA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | -3.3% | -0.4% |
| 1Y | 182.5% | -2.7% | 24.8% |
Return vs Industry: TARA exceeded the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: TARA exceeded the US Market which returned 23.9% over the past year.
Price Volatility
| TARA volatility | |
|---|---|
| TARA Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TARA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TARA's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 27 | Jesse Shefferman | www.protaratx.com |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.
Protara Therapeutics, Inc. Fundamentals Summary
| TARA fundamental statistics | |
|---|---|
| Market cap | US$106.66m |
| Earnings (TTM) | -US$42.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs TARA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.05m |
| Earnings | -US$42.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TARA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:38 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Protara Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Etzer Darout | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |